0
Following
10
Follower
0
Boost

Point of Care Diagnostics Market - In Depth Analysis of Industry Segments, Growth Drivers and Key Players

Growth Factors Driving the Market: The Point of Care Diagnostics Market growth is mainly driven by the high prevalence of infectious diseases, supportive government policies and rising number of CLIA-waived POC tests. In addition, healthcare decentralization and greater investments and funding for product development are expected to offer growth opportunities for players in the point of care diagnostics market. However, issues related to pricing pressure owing to reimbursement cuts and budget constraints are expected to hinder the growth of the point of care diagnostics market during the forecast period. MarketsandMarkets™ View on Revenue: The global point of care and rapid diagnostics market is expected to reach USD 72.0 billion by 2027 from an estimated USD 43.2 billion in 2022, at a CAGR of 10.8% from 2022 to 2027. Industry Segmentation in Detailed: The Glucose Monitoring Products segment accounted for the largest share of the point of care diagnostics market. Based on products, the point-of-care diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, COVID-19 testing products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, hematology testing products, tumor/cancer marker testing products, fecal occult testing products, urinalysis testing products, drug-of-abuse testing products, cholesterol testing products, and other products. In 2021, the glucose monitoring products segment accounted for the largest share of the point-of-care diagnostics market. This can be attributed to the growing diabetic patient population base, ongoing technological advancements, and the growing preference for home glucose testing. The Lateral Flow Assays segment accounted for the largest share of the poc diagnostics market.
Health
News
+ 1 interests

Lateral Flow Assays Market Analysis, Top 10 Company Profiles, Regional Revenue and Forecast to 2026

Growth Factors Driving the Market: The high prevalence of infectious diseases worldwide, rapid growth in the geriatric population, growing demand for point-of-care testing, and rising use of home-based lateral flow assay devices are the major factors driving the growth of this market. On the other hand, reluctance among doctors and patients to change existing diagnostic procedures and the low accuracy of lateral flow assays are the key restraints. The high prevalence of infectious diseases, such as HIV and malaria, coupled with the underdeveloped healthcare infrastructural facilities and increasing public awareness in developing countries, is expected to drive the adoption of lateral flow assay tests in these countries. In addition, recent outbreaks of infectious diseases from the spread of viruses (such as Ebola, H1N1, and Zika) have highlighted the need for early disease detection capabilities, which is also expected to drive market growth. The current COVID-19 pandemic has resulted in high demand for rapid diagnostic testing through lateral flow technology, supporting the growth of this market in the coming year. MarketsandMarkets™ View on Revenue: The global lateral flow assays market is projected to reach USD 12.6 billion by 2026, at a CAGR of 2.0% during the forecast period. Industry Segmentation in Detailed: The Rising demand for lateral flow assays in the food & beverage industry; Food safety issues and concerns for public health have led to the implementation of more stringent legislation for food safety in several countries. This resulted in an increased demand for pathogen and toxin tests in just about every segment of the food production industry—processed foods, meats, poultry, beverages, and dairy—and among all major food producers worldwide.
Health
News
+ 1 interests

Breast Reconstruction Market - Future Growth, Comprehensive Analysis & Key Players

Growth Factors Driving the Market: The emergence of 3D-printed implants can provide significant opportunities for market growth. German companies, BellaSeno and Evonik, have entered into a collaboration to develop 3D breast implant technology. BellaSeno will use Evonik’s Resomer bioresorbable polymer in its Senella breast scaffolds, avoiding the use of silicone implants that have raised major safety concerns. BellaSeno planned to start the first human clinical trials of the Senella scaffolds with Resomer in Germany in 2019. Evonik has supplied its Resomer polymer for clinical and commercial use. The scaffolds are designed to guide the growth of the natural tissue using the patient's body fat harvested via liposuction. This product is designed to be used after augmentation, reconstruction, and revision surgery. This is progressively reabsorbed by the body and replaced with natural breast tissue. This technology avoids the use of silicone implants and their associated complications & risk, like capsular contracture, rupture, and deflation. Moreover, in December 2021, Bellaseno GmbH reported the publication of first-in-human data for its 3D-printed biodegradable and highly porous Senella scaffold filled with an autologous fat graft to correct a chest deformation in a 22-year-old patient with severe pectus excavatum. The article was published in the European Journal of Plastic Surgery. MarketsandMarkets™ View on Revenue: The global breast reconstruction market size is expected to grow from USD 647 million by 2026 to USD 567 million in 2021, at a CAGR of 2.7%. Industry Segmentation in Detailed: "Breast implants accounted for the largest share of the breast reconstruction market" Based on the product, the breast reconstruction market is segmented into breast implants, tissue expanders, and acellular dermal matrix. The breast implants segment accounted for the largest market share in 2020.
Health
News
+ 1 interests

Growth Strategies Adopted by Key Players in the Global Contract Research Organization Services Market

Growth Factors Driving the Market: The Growth in CRO services market can mainly be attributed to factors such as the increasing investment in pharmaceutical R&D, rising number of clinical trials, high cost of in-house drug development (encouraging pharma-biotech companies to opt for outsourcing), and the rising prevalence of orphan and rare diseases (creating new revenue pockets for CROs). Growth in the drugs and biologics market despite the COVID-19 pandemic, the increasing demand for specialized testing services among end users, and the need for novel clinical trial designs for complex cell and gene therapies are also expected to offer a wide range of growth opportunities to players operating in this market. MarketsandMarkets™ View on Revenue: The Global Contract Research Organization (CROs) Services Market is estimated to grow from USD 115.1 billion by 2027 from USD 68.3 billion in 2022, at a CAGR of 11.0% during the forecast period. Industry Segmentation in Detailed: The clinical research services subsegment accounted for the largest share of the type segment in the CRO services market in 2021. Based on type, the CRO services market is segmented into clinical research services, early-phase development services, laboratory services, consulting services, and data management services. The clinical research services segment accounted for the largest share of this market in 2021. The large share of this segment can primarily be attributed to factors such as the increasing R&D of new drugs and the high cost of clinical trials. The oncology subsegment accounted for the largest share of the therapeutic area segment in the CRO services market in 2021.
Health
News
+ 1 interests

Aptamers Market Size, Share, Trends and Global Forecast 2026

Growth Factors Driving the Market: The Growth of aptamers market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages of aptamers as compared to antibodies, rising investment in pharmaceutical R&D, and rising prevalence of chronic and rare diseases to increase the demand for aptamer-based therapeutics and diagnostics. Growth in the venture capital funding for research on aptamers and growing collaborations with research institutes and pharmaceutical companies are also expected to offer a wide range of growth opportunities to players in the market. On the other hand, low market acceptance as compared to antibodies is likely to restrain the market growth while shortage of skilled & trained professionals may challenge market growth to a certain extent. MarketsandMarkets™ View on Revenue: The aptamers market valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period. Industry Segmentation in Detailed: “The therapeutics development segment will continue to dominate the aptamers application market during the forecast period” Based on the application, the aptamers market is segmented into therapeutics development, research & development, diagnostics, and other applications. In 2020, the therapeutics development segment dominated the market due to the increasing number of clinical trials evaluating aptamers for new therapies and collaborations among aptamer companies & prominent pharmaceutical and biotechnology firms. The diagnostic segment is projected to grow at the highest CAGR due to the increasing prevalence of chronic diseases and the development of new diagnostic kits to detect cancer and other diseases. "Pharmaceutical & biotechnology companies are the largest end users of aptamers technology"
Health
News
+ 1 interests

Aptamers Market - Global Industry Leaders & Growth Strategies Adopted

According to the new market research report “Aptamers Market by Product Type (DNA, RNA, XNA), Technology (SELEX), Application (Therapeutics, Diagnostics, R&D), End Users (Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, CROs) – Global Forecast to 2026″, published by MarketsandMarkets™, is valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period. Drivers: Rising awareness of the advantages of aptamers over antibodies; While antibodies have certain limitations in targeting small molecules, aptamers perform better in targeting small molecules. They can bind to small molecules and dyes and thus be easily used in conventional diagnostic kits, extending their use to point-of-care diagnostics. This, in turn, will ensure a greater market value and increase in acceptance of aptamers in addressing both therapeutic and diagnostic applications. Also, aptamers can bind to large molecules. Nearly 98% of the molecules tend to be proteins, making it easier to discover biomarkers and diagnostic kits. Antibodies are developed by raising an immune response in an animal model or recombinant DNA technology. On the other hand, aptamers can be synthesized using chemical methods which are less costly. Therefore, aptamers are more appealing for the development of new therapeutic drugs and diagnostic kits. The blood-brain barrier has been a great challenge for antibody-based treatment for neurodegenerative disorders such as Alzheimer’s. Although technological developments have bridged the gap for this challenge, the effectiveness of antibodies against these disorders remains intact. Aptamers are short oligonucleotides that can diffuse across this blood-brain barrier and show potential in treating neurodegenerative disorders. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1167
Health
News
+ 1 interests